Actual LIBTAYO patient and caregiver

Actual LIBTAYO patient and caregiver.

LIBTAYO used alone compared with chemotherapy alone

LIBTAYO was studied in a clinical trial that compared adult patients with advanced NSCLC who received LIBTAYO with those who received chemotherapy.

The study was designed to include adult patients if their tumor tested positive for the biomarker PD-L1 at a level greater than or equal to 50% and if they did not have abnormal EGFR, ALK, or ROS1 genes.

A total of
710 patients
were included in the study

356 patients were given LIBTAYO 350 mg every 3 weeks

354 patients were given chemotherapy containing platinum

As a first treatment, LIBTAYO used alone was proven to help patients live longer versus chemotherapy used alone

Median overall survival (OS)*

AT 22.1 MONTHS
half of the patients
taking LIBTAYO
(178 out of 356 patients)
were alive
VS
AT 14.3 MONTHS
half of the patients
taking chemotherapy
(177 out of 354 patients)
were alive

*Median overall survival (OS) is the time in a trial—expressed in months or years—when half of the patients are still living.

More patients were alive with LIBTAYO

As of March 2020, results from the trial showed that more patients taking LIBTAYO were alive compared with chemotherapy alone.

248 out of 356
patients (70%)
with LIBTAYO
VS
213 out of 354
patients (60%) with
chemotherapy alone

Patients were enrolled on an ongoing basis between May 29, 2017, and March 1, 2020. Patients were treated with LIBTAYO for an average of 27 weeks. The study is still ongoing, and patients will be followed up with for up to 4 years.

LIBTAYO used alone reduced the chance of advanced NSCLC progressing compared with chemotherapy alone

LIBTAYO used alone reduced the risk of cancer spreading, growing, or getting worse by 41% compared with chemotherapy alone.

Median progression-free survival (PFS)

AT 6.2 MONTHS
half of the patients taking
LIBTAYO were alive
without their cancer spreading,
growing, or getting worse
VS
AT 5.6 MONTHS
half of the patients taking
chemotherapy were alive
without their cancer spreading,
growing, or getting worse

Median progression-free survival (PFS) is the time in a trial—expressed in months or years—when half of the patients are still living without their cancer spreading, growing, or getting worse.

As of March 2020, advanced NSCLC had not progressed in more patients taking LIBTAYO compared with chemotherapy alone.§

155 out of 356
patients (43%)
with LIBTAYO
VS
92 out of 354
patients (26%) with
chemotherapy alone§

§Patients were enrolled on an ongoing basis between May 29, 2017, and March 1, 2020. Patients were treated with LIBTAYO for an average of 27 weeks. The study is still ongoing, and patients will be followed up with for up to 4 years.

Individual results may vary.

Review the most common side effects of LIBTAYO used alone.

See side effects from the study